Chris Johnson is Clinical Director for Thoracic and Ambulatory Services at Royal Papworth Hospital and Consultant to the Adult Cystic Fibrosis Unit and Lung Defence and Immunology Service.
The Lung Defence Clinic oversees the care of >2500 patients with bronchiectasis associated with primary and secondary immunodeficiencies, chronic Pseudomonal infection, non-tuberculous mycobacterial (NTM) lung disease, Aspergillus related lung disease, rheumatoid arthritis, serious childhood infection, chronic aspiration and primary ciliary dyskinesia.
The Adult Cystic Fibrosis Unit oversees the care of >425 patients with Cystic Fibrosis living in East Anglia and beyond. Both services provide inpatient care, outpatient reviews and a comprehensive home intravenous antibiotic service supported by Specialist Nursing, Physiotherapy and Dietetic teams.
• Cystic Fibrosis
• Bronchiectasis
• Asthma / COPD with infection
• Complex lung infection (including Pseudomonas aeruginosa, non-Tuberculous Mycobacteria and Aspergillus)
• Primary Ciliary Dyskinesia
• Immunodeficiency
- Real World Evidence using data from Electronic Patient Records
- Immunogenetics of airways diseases
- Genetics of non-CF bronchiectasis
- The Major Histocompatibility and Leucocyte Receptor Complexes and their role in human disease
• 1997 BA University of Cambridge
• 2000 BM BCh University of Oxford
• 2001 MA University of Cambridge
• 2004 MRCP UK (London)
• 2005 Wellcome Trust Clinical Research Training Fellowship
• 2012 CCST in Respiratory and General Internal Medicine
• 2012 Post CCT Clinical Fellowship in Cystic Fibrosis and Lung Infection - Papworth Hospital, University of North Carolina, National Jewish Hospital in Denver
- Fellow of the Royal College of Surgeons, London.
- Member of the General Medical Council (registration number: 4732390)
- Member of the British Thoracic Society
- Member of the European Respiratory Society
- Member of the European CF society
Alfahl Z, Einarsson GG, Elborn JS, Gilpin DF, O'Neill K, Ferguson K, Hill AT, Loebinger MR, Carroll M, Gatheral T, De Soyza A, Chalmers JD, Johnson C, Hurst JR, Brown JS, Bradley JM, Tunney MM. Airway total bacterial density, microbiota community composition and relationship with clinical parameters in bronchiectasis. Respir Med. 2024 Dec 4;236:107906. doi: 10.1016/j.rmed.2024.107906. Online ahead of print.PMID: 39643125
Bradley JM, Ferguson K, Bailey A, O'Neill K, McLeese RH, Hill AT, Loebinger MR, Carroll M, Chalmers JD, Gatheral T, Johnson C, De Soyza A, Hurst JR, Downey DG, Elborn JS. Clinimetric Properties of Outcome Measures in Bronchiectasis. Ann Am Thorac Soc. 2023 May;20(5):648-659. doi: 10.1513/AnnalsATS.202206-493OC.
O'Neill K, Lakshmipathy GR, Neely C, Cosgrove D, Ferguson K, McLeese R, Hill AT, Loebinger MR, Carroll M, Chalmers JD, Gatheral T, Johnson C, De Soyza A, Hurst JR, Bradbury I, Elborn JS, Bradley JM. Multiple-Breath Washout Outcome Measures in Adults with Bronchiectasis. Ann Am Thorac Soc. 2022 Sep;19(9):1489-1497. doi: 10.1513/AnnalsATS.202006-584OC.
The BRICS (Bronchiectasis Radiologically Indexed CT Score)- a multi centre study score for use in idiopathic and post infective bronchiectasis. Chest. 2018 May;153(5):1177-1186. doi: 10.1016/j.chest.2017.11.033. Epub 2017 Dec 13.
Chalmers J., Polverino E., Aliberti S, Johnson C (eds). Long-Term Inhaled Antibiotic Treatment in Bronchiectasis. 2018. Bronchiectasis. Springer, Cham
Management of bronchiectasis in Europe: Data from the European bronchiectasis registry (EMBARC)Charles S. Haworth, Chris Johnson, Stefano Aliberti, Pieter C. Goeminne, Felix Ringhausen, Wim Boersma, Anthony De Soyza, Marlene Murris, Eva Polverino, Montserrat Vendrell, James D. Chalmers. European Respiratory Journal 2016 48: OA273
Bronchiectasis. 2016. Medicine.
LILRA6 copy number correlates with susceptibility to atopic dermatitis. 2016. Immunogenetics 68(9):743-7.
KIR haplotypes are associated with late-onset type 1 diabetes in European-American families. 2016. Genes and Immunity 17(1):8-12.
Inhaled antibiotics for bronchiectasis: are we there yet? 2015. Curr Pulmonol Rep 4:198–204
The development of a website to facilitate transition from paediatric to adult CF services. 2015. Journal of Cystic Fibrosis, Vol. 14, S9
Copy number variation leads to considerable diversity for B but not A haplotypes of the human KIR genes encoding NK cell receptors. 2012. Genome Research, 22(10):1845-54.
Genetic determinants of ulcerative colitis include the ECM1 locus and five loci implicated in Crohn's disease. 2008. Nature Genetics, 40(6), 710-712.
Jiang W, Johnson C, Jayaraman J, Trowsdale J, Traherne JA. (2012). Extensive diversity of human innate immune genes revealed by typing for copy number variation. Genome Research, 22(10), 1845-1854.
Fisher SA, Tremelling M, Anderson CA, Gwilliam R, Bumpstead S, Prescott NJ, Nimmo ER, Massey D, Berzuini C, Johnson C, Barrett JC, Cummings FR, Drummond H, Lees CW, Onnie CM, Hanson CE, Blaszczyk K, Inouye M, Ewels P, Ravindrarajah R, Keniry A, Hunt S, Carter M, Watkins N, Ouwehand W, Lewis CM, Cardon L; Wellcome Trust Case Control Consortium, Lobo A, Forbes A, Sanderson J, Jewell DP, Mansfield JC, Deloukas P, Mathew CG, Parkes M, Satsangi J. (2008). Genetic determinants of ulcerative colitis include the ECM1 locus and five loci implicated in Crohn's disease. Nature Genetics, 40(6), 710-712.
Johnson CM, Traherne JA, Jamieson SE, Tremelling M, Bingham S, Parkes M, Blackwell JM, Trowsdale J. (2007). Analysis of the BTNL2 truncating splice site mutation in tuberculosis, leprosy and Crohn’s disease. Tissue Antigens, 69(3), 236-241.
